The VOICE Study – Vaginal and Oral Interventions to Control the Epidemic – was designed to evaluate the safety and effectiveness of two antiretroviral (ARV)-based approaches for preventing sexual transmission of HIV in women as well as determining which of these women are more likely to follow: applying vaginal gel (tenofovir gel) daily or taking an ARV tablet (tenofovir or Truvada®) once a day. VOICE also includes two sub-studies: VOICE B (Bone Mineral Density) and VOICE C (Household and Community Factors Associated with Adherence).
The oral tenofovir and tenofovir gel arms of VOICE were dropped following interim reviews of data that determined neither product was effective in the women assigned to those study groups. Truvada continues to be evaluated. The study is expected to be completed in August 2012 and final results to be reported early 2013.
Nov 25, 2011
Nov 25, 2011
Please note that the information contained in the following news releases and materials may have changed since publication.
Nov 1, 2011
Oct 28, 2011
Sep 28, 2011
Sep 28, 2011
Jul 14, 2011
Jul 13, 2011
Jul 13, 2011
Jun 6, 2011
Apr 18 2011
Nov 23, 2010
Jul 19, 2010
Sep 16, 2009
Sep 16, 2009
Jul 20, 2009
VOICE B (Bone Mineral Density Sub-study)
VOICE C (Community and Adherence Sub-study)
Understanding Resistance
Diagrams:
See Also
